Comparative Risk of Metabolic Adverse Outcomes in Patients with Schizophrenia Spectrum Disorder Treated with Aripiprazole Versus Olanzapine: A Retrospective Cohort Study Using the Global TriNetX Network
Cameron Asay, Kypros Dereschuk & Eduardo Espiridion · Journal of Advances in Medicine and Medical Research · 2025
Introduction: Second-generation antipsychotics manage schizophrenia spectrum disorders but carry metabolic risks. Olanzapine is associated with greater metabolic liability, while aripiprazole is considered more metabolically neutral. This study compares the risk of developing hyp...
Open access
Research Article
10.9734/jammr/2025/v37i126007